Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study
Summary Background Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. Aim To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient group...
Saved in:
Published in | Alimentary pharmacology & therapeutics Vol. 38; no. 3; pp. 264 - 273 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Blackwell
01.08.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Background
Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis.
Aim
To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent of lesions.
Methods
This study was a phase III multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group study. Mild‐to‐moderate UC patients with rectal inflammation were randomly assigned either a 1 g mesalazine or placebo suppository. The suppository was administered in the rectum once daily for 4 weeks. The primary efficacy end point was the rate of endoscopic remission (mucosal score of 0 or 1) after 4 weeks.
Results
The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi‐squared test). For proctitis, the endoscopic remission rates after 4 weeks were 83.8% and 36.1% in the mesalazine and placebo suppository groups, respectively, and the corresponding rates for all other types of UC were 78.6% and 21.4%, respectively. The superiority of mesalazine to placebo was confirmed in both subgroups (P < 0.0001, Fisher's exact test). The percentage of patients without bleeding was significantly higher in the mesalazine group than the placebo group from Day 3 of treatment (P = 0.0001, Fisher's exact test).
Conclusions
The effectiveness of mesalazine suppositories in all types of UC patients with rectal inflammation was confirmed for the first time in a double‐blind, placebo‐controlled, parallel‐group study (JapicCTI‐ 111421). |
---|---|
AbstractList | Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent of lesions. This study was a phase III multicentre, randomised, double-blind, placebo-controlled, parallel-group study. Mild-to-moderate UC patients with rectal inflammation were randomly assigned either a 1 g mesalazine or placebo suppository. The suppository was administered in the rectum once daily for 4 weeks. The primary efficacy end point was the rate of endoscopic remission (mucosal score of 0 or 1) after 4 weeks. The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi-squared test). For proctitis, the endoscopic remission rates after 4 weeks were 83.8% and 36.1% in the mesalazine and placebo suppository groups, respectively, and the corresponding rates for all other types of UC were 78.6% and 21.4%, respectively. The superiority of mesalazine to placebo was confirmed in both subgroups (P < 0.0001, Fisher's exact test). The percentage of patients without bleeding was significantly higher in the mesalazine group than the placebo group from Day 3 of treatment (P = 0.0001, Fisher's exact test). The effectiveness of mesalazine suppositories in all types of UC patients with rectal inflammation was confirmed for the first time in a double-blind, placebo-controlled, parallel-group study (JapicCTI- 111421). Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent of lesions. This study was a phase III multicentre, randomised, double-blind, placebo-controlled, parallel-group study. Mild-to-moderate UC patients with rectal inflammation were randomly assigned either a 1 g mesalazine or placebo suppository. The suppository was administered in the rectum once daily for 4 weeks. The primary efficacy end point was the rate of endoscopic remission (mucosal score of 0 or 1) after 4 weeks. The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi-squared test). For proctitis, the endoscopic remission rates after 4 weeks were 83.8% and 36.1% in the mesalazine and placebo suppository groups, respectively, and the corresponding rates for all other types of UC were 78.6% and 21.4%, respectively. The superiority of mesalazine to placebo was confirmed in both subgroups (P < 0.0001, Fisher's exact test). The percentage of patients without bleeding was significantly higher in the mesalazine group than the placebo group from Day 3 of treatment (P = 0.0001, Fisher's exact test). The effectiveness of mesalazine suppositories in all types of UC patients with rectal inflammation was confirmed for the first time in a double-blind, placebo-controlled, parallel-group study (JapicCTI- 111421). BACKGROUNDMesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis.AIMTo evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent of lesions.METHODSThis study was a phase III multicentre, randomised, double-blind, placebo-controlled, parallel-group study. Mild-to-moderate UC patients with rectal inflammation were randomly assigned either a 1 g mesalazine or placebo suppository. The suppository was administered in the rectum once daily for 4 weeks. The primary efficacy end point was the rate of endoscopic remission (mucosal score of 0 or 1) after 4 weeks.RESULTSThe endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi-squared test). For proctitis, the endoscopic remission rates after 4 weeks were 83.8% and 36.1% in the mesalazine and placebo suppository groups, respectively, and the corresponding rates for all other types of UC were 78.6% and 21.4%, respectively. The superiority of mesalazine to placebo was confirmed in both subgroups (P < 0.0001, Fisher's exact test). The percentage of patients without bleeding was significantly higher in the mesalazine group than the placebo group from Day 3 of treatment (P = 0.0001, Fisher's exact test).CONCLUSIONSThe effectiveness of mesalazine suppositories in all types of UC patients with rectal inflammation was confirmed for the first time in a double-blind, placebo-controlled, parallel-group study (JapicCTI- 111421). Summary Background Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. Aim To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent of lesions. Methods This study was a phase III multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group study. Mild‐to‐moderate UC patients with rectal inflammation were randomly assigned either a 1 g mesalazine or placebo suppository. The suppository was administered in the rectum once daily for 4 weeks. The primary efficacy end point was the rate of endoscopic remission (mucosal score of 0 or 1) after 4 weeks. Results The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi‐squared test). For proctitis, the endoscopic remission rates after 4 weeks were 83.8% and 36.1% in the mesalazine and placebo suppository groups, respectively, and the corresponding rates for all other types of UC were 78.6% and 21.4%, respectively. The superiority of mesalazine to placebo was confirmed in both subgroups (P < 0.0001, Fisher's exact test). The percentage of patients without bleeding was significantly higher in the mesalazine group than the placebo group from Day 3 of treatment (P = 0.0001, Fisher's exact test). Conclusions The effectiveness of mesalazine suppositories in all types of UC patients with rectal inflammation was confirmed for the first time in a double‐blind, placebo‐controlled, parallel‐group study (JapicCTI‐ 111421). |
Author | Watanabe, M. Nakamura, S. Ota, A. Sameshima, Y. Nishino, H. Hibi, T. |
Author_xml | – sequence: 1 givenname: M. surname: Watanabe fullname: Watanabe, M. organization: Graduate School of Tokyo Medical and Dental University – sequence: 2 givenname: H. surname: Nishino fullname: Nishino, H. organization: Colo‐Proctology Center Matsushima Clinic – sequence: 3 givenname: Y. surname: Sameshima fullname: Sameshima, Y. organization: Sameshima Hospital – sequence: 4 givenname: A. surname: Ota fullname: Ota, A. organization: Ieda Hospital – sequence: 5 givenname: S. surname: Nakamura fullname: Nakamura, S. organization: Hyogo College of Medicine – sequence: 6 givenname: T. surname: Hibi fullname: Hibi, T. organization: Keio University |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27491849$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23734840$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtuFDEQhi0URB6w4ALIG6RkMYkfPZ5udlHES4oEQmHdqqmuVozcdmO7Ew2rHAGJG3GUnARPeoAVEt64qvTp_0v1H7I9Hzwx9lyKU1neGYz5VCpt1CN2ILVZLpTQZo8dCGWahaql3meHKX0RQpiVUE_YvtIrXdWVOGA_P4HvwmATdRyd9RbB8RwtuFecbsBNkG3wPPQ8XxOnvi8Abrb9QAkcfLOe-PFcD6U-4Wkax5BsDtFS4tbzsUiQz4nf2nzNJ4cUy-SGOAZns028bMABH0aRMJcFrO-L3DB739_94MBHB0jrcH_3HYPPMThXNk556jZP2eMeXKJnu_-IfX7z-uri3eLyw9v3F-eXC9R1rRYNoAHdi7XRuMKmqpakCKETugZZZlh3GnQnoAclscG-QS0rIbE33XoFRh-x41l3jOHrRCm35WxIzoGnMKVWVst6qYwR_4Fu76-Xum4KejKjGENKkfp2jHaAuGmlaLfptiXd9iHdwr7YyU7rgbo_5O84C_ByB0AqQfYRPNr0l1tVjayrrenZzN1aR5t_O7bnH69m61-XH8SI |
CitedBy_id | crossref_primary_10_1007_s00535_017_1376_4 crossref_primary_10_5217_ir_2017_15_1_7 crossref_primary_10_1186_s13063_020_05012_8 crossref_primary_10_3109_00365521_2014_968864 crossref_primary_10_1016_j_crphar_2021_100071 crossref_primary_10_1016_j_rgmxen_2016_07_003 crossref_primary_10_1016_j_gastrohep_2019_10_004 crossref_primary_10_3390_jcm12216929 crossref_primary_10_1097_MIB_0000000000000141 crossref_primary_10_1080_00325481_2017_1319730 crossref_primary_10_1093_crocol_otaa030 crossref_primary_10_1055_a_1296_3494 crossref_primary_10_1097_DCR_0000000000001834 crossref_primary_10_1007_s00535_021_01784_1 crossref_primary_10_1038_srep46693 crossref_primary_10_1111_jgh_14052 crossref_primary_10_1159_000533543 crossref_primary_10_1002_ueg2_12283 crossref_primary_10_1111_apt_14688 crossref_primary_10_1080_14712598_2024_2369189 crossref_primary_10_1517_14656566_2014_920322 crossref_primary_10_1080_17474124_2018_1530109 crossref_primary_10_1055_a_1296_3444 crossref_primary_10_1016_j_bpg_2018_05_009 crossref_primary_10_4166_kjg_2017_69_1_1 crossref_primary_10_1016_j_rgmx_2016_07_003 crossref_primary_10_1097_MIB_0000000000000379 crossref_primary_10_1016_j_gastrohep_2019_01_013 crossref_primary_10_1111_apt_13308 crossref_primary_10_1177_20587392211015108 crossref_primary_10_1055_s_0041_1740037 crossref_primary_10_1007_s00228_022_03312_3 crossref_primary_10_1136_gutjnl_2021_324108 crossref_primary_10_1097_MIB_0000000000000562 crossref_primary_10_1055_a_2060_0935 crossref_primary_10_1111_apt_14672 crossref_primary_10_1111_apt_17666 crossref_primary_10_1093_ecco_jcc_jjab010 crossref_primary_10_1016_j_gastre_2019_10_005 crossref_primary_10_1093_ecco_jcc_jjab218 crossref_primary_10_1093_ecco_jcc_jjac109 crossref_primary_10_1097_MEG_0000000000002444 crossref_primary_10_1016_j_gastre_2017_05_009 crossref_primary_10_1016_j_cgh_2017_08_025 crossref_primary_10_1016_j_crohns_2014_05_005 crossref_primary_10_1055_a_2271_0994 crossref_primary_10_1097_MPG_0000000000002035 crossref_primary_10_1093_ecco_jcc_jjw004 crossref_primary_10_1016_j_gastrohep_2017_05_006 crossref_primary_10_1159_000484224 crossref_primary_10_1016_j_gastre_2019_01_016 crossref_primary_10_1007_s00535_018_1439_1 crossref_primary_10_1053_j_gastro_2015_03_001 crossref_primary_10_1002_14651858_CD011572_pub2 |
Cites_doi | 10.1097/00042737-199606000-00011 10.1007/BF02236902 10.1046/j.1365-2036.1997.126297000.x 10.1155/1990/689834 10.1038/ajg.2009.727 10.1016/j.crohns.2012.09.002 10.1007/BF00298473 10.3109/00365529008997590 10.1097/01.MIB.0000225339.91484.fc 10.1007/BF01312468 10.1016/0016-5085(87)90621-4 10.1111/j.1365-2036.1988.tb00668.x 10.3109/00365529609004876 10.1056/NEJM198712243172603 |
ContentType | Journal Article |
Copyright | 2013 John Wiley & Sons Ltd 2014 INIST-CNRS 2013 John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2013 John Wiley & Sons Ltd – notice: 2014 INIST-CNRS – notice: 2013 John Wiley & Sons Ltd. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 F1W H95 L.G |
DOI | 10.1111/apt.12362 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) Professional |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) Professional ASFA: Aquatic Sciences and Fisheries Abstracts |
DatabaseTitleList | Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 273 |
ExternalDocumentID | 10_1111_apt_12362 23734840 27491849 APT12362 |
Genre | article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Kyorin Pharmaceutical Co., Ltd |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAJUZ AAVGM ABCVL ABFLS ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW RIG UMP ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 F1W H95 L.G |
ID | FETCH-LOGICAL-c3882-9ac6a3f0b63c7c9445e2ecad038a163cc8d3a3d0afa21c9cf9c31401cf6db7a63 |
IEDL.DBID | DR2 |
ISSN | 0269-2813 |
IngestDate | Fri Aug 16 04:47:01 EDT 2024 Sat Aug 17 03:31:58 EDT 2024 Fri Aug 23 03:05:10 EDT 2024 Thu May 23 23:19:40 EDT 2024 Tue Sep 20 22:54:10 EDT 2022 Sat Aug 24 01:13:22 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Human Prostaglandin-endoperoxide synthase Evaluation Enzyme Treatment efficiency Enzyme inhibitor Inflammation Rectal administration Inflammatory disease Non steroidal antiinflammatory agent Analgesic Mesalazine Placebo Rectum Dosage form Antipyretic Digestive diseases Intestinal disease Clinical trial Oxidoreductases Salicylates Suppository Ulcerative colitis |
Language | English |
License | CC BY 4.0 2013 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3882-9ac6a3f0b63c7c9445e2ecad038a163cc8d3a3d0afa21c9cf9c31401cf6db7a63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 23734840 |
PQID | 1373435389 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1458526606 proquest_miscellaneous_1373435389 crossref_primary_10_1111_apt_12362 pubmed_primary_23734840 pascalfrancis_primary_27491849 wiley_primary_10_1111_apt_12362_APT12362 |
PublicationCentury | 2000 |
PublicationDate | August 2013 |
PublicationDateYYYYMMDD | 2013-08-01 |
PublicationDate_xml | – month: 08 year: 2013 text: August 2013 |
PublicationDecade | 2010 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2013 |
Publisher | Blackwell |
Publisher_xml | – name: Blackwell |
References | 1988; 2 1987; 32 1990; 25 2006; 12 1997; 11 2010; 105 1987; 92 1987; 317 1992; 16 2012; 6 1998; 41 1996; 8 1996; 31 1990; 5 1990; 4 Gionchetti (10.1111/apt.12362-BIB0012|apt12362-cit-0012) 1998; 41 Henriksen (10.1111/apt.12362-BIB0005|apt12362-cit-0005) 2006; 12 Sutherland (10.1111/apt.12362-BIB0013|apt12362-cit-0013) 1987; 92 Schroeder (10.1111/apt.12362-BIB0014|apt12362-cit-0014) 1987; 317 Ayres (10.1111/apt.12362-BIB0004|apt12362-cit-0004) 1996; 8 Henriksen (10.1111/apt.12362-BIB0018|apt12362-cit-0018) 2006; 12 Campieri (10.1111/apt.12362-BIB0010|apt12362-cit-0010) 1990; 25 Langholz (10.1111/apt.12362-BIB0003|apt12362-cit-0003) 1996; 31 Langholz (10.1111/apt.12362-BIB0016|apt12362-cit-0016) 1996; 31 Ngô (10.1111/apt.12362-BIB0011|apt12362-cit-0011) 1992; 16 Ayres (10.1111/apt.12362-BIB0017|apt12362-cit-0017) 1996; 8 Lucidarme (10.1111/apt.12362-BIB0015|apt12362-cit-0015) 1997; 11 Dignass (10.1111/apt.12362-BIB0002|apt12362-cit-0002) 2012; 6 Hogezand (10.1111/apt.12362-BIB0007|apt12362-cit-0007) 1988; 2 Kornbluth (10.1111/apt.12362-BIB0001|apt12362-cit-0001) 2010; 105 Campieri (10.1111/apt.12362-BIB0009|apt12362-cit-0009) 1990; 5 Williams (10.1111/apt.12362-BIB0006|apt12362-cit-0006) 1987; 32 Williams (10.1111/apt.12362-BIB0008|apt12362-cit-0008) 1990; 4 |
References_xml | – volume: 11 start-page: 335 year: 1997 end-page: 40 article-title: Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis publication-title: Aliment Pharmacol Ther – volume: 5 start-page: 79 year: 1990 end-page: 81 article-title: Topical treatment with 5‐aminosalicylic in distal UC by using a new suppository preparation. A double‐blind placebo controlled trial publication-title: Int J Colorectal Dis – volume: 25 start-page: 663 year: 1990 end-page: 8 article-title: Mesalazine (5‐aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial publication-title: Scand J Gastroenterol – volume: 41 start-page: 93 year: 1998 end-page: 7 article-title: Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis publication-title: Dis Colon Rectum – volume: 317 start-page: 1625 year: 1987 end-page: 9 article-title: Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active UC. A randomized study publication-title: N Engl J Med – volume: 8 start-page: 555 year: 1996 end-page: 8 article-title: Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression publication-title: Eur J Gastroenterol Hepatol – volume: 32 start-page: 71S year: 1987 end-page: 5S article-title: Double‐blind, placebo‐controlled evaluation of 5‐ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc‐labeled 5‐ASA suppositories publication-title: Dig Dis Sci – volume: 12 start-page: 543 year: 2006 end-page: 50 article-title: UC and clinical course: results of a 5‐year population‐based followed‐up study (The IBSEN Study) publication-title: Inflamm Bowel Dis – volume: 12 start-page: 543 year: 2006 end-page: 50 article-title: UC and clinical course: results of a 5‐year population‐based follow‐up study (the IBSEN study) publication-title: Inflamm Bowel Dis – volume: 4 start-page: 472 year: 1990 end-page: 5 article-title: Efficacy and tolerance of 5‐aminosalicylic acid suppositories in the treatment of ulcerative proctitis: a review of two double‐blind, placebo controlled trials publication-title: Can J Gastroenterol – volume: 31 start-page: 260 year: 1996 end-page: 6 article-title: Changes in extent of UC: a study on the course and prognostic factors publication-title: Scand J Gastroenterol – volume: 16 start-page: 782 year: 1992 end-page: 6 article-title: Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double‐blind versus placebo randomized trial publication-title: Gastroenterol Clin Biol – volume: 2 start-page: 33 year: 1988 end-page: 40 article-title: Double‐blind comparison of 5‐aminosalicylic acid and acetyl‐5‐aminosalicylic acid suppositories in patients with idiopathic proctitis publication-title: Aliment Pharmacol Ther – volume: 31 start-page: 260 year: 1996 end-page: 6 article-title: Changes in extent of UC publication-title: Scand J Gastroenterol – volume: 105 start-page: 501 year: 2010 end-page: 23 article-title: UC practice guidelines in adults: American college of gastroenterology, practice parameters committee publication-title: Am J Gastroenterol – volume: 92 start-page: 1894 year: 1987 end-page: 8 article-title: 5‐Aminosalicylic acid enema in the treatment of distal UC, proctosigmoiditis, and proctitis publication-title: Gastroenterology – volume: 6 start-page: 991 year: 2012 end-page: 1030 article-title: Second European evidence‐based consensus on the diagnosis and management of UC: current management publication-title: J Crohns Colitis – volume: 8 start-page: 555 year: 1996 ident: 10.1111/apt.12362-BIB0017|apt12362-cit-0017 article-title: Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/00042737-199606000-00011 contributor: fullname: Ayres – volume: 41 start-page: 93 year: 1998 ident: 10.1111/apt.12362-BIB0012|apt12362-cit-0012 article-title: Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis publication-title: Dis Colon Rectum doi: 10.1007/BF02236902 contributor: fullname: Gionchetti – volume: 11 start-page: 335 year: 1997 ident: 10.1111/apt.12362-BIB0015|apt12362-cit-0015 article-title: Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.1997.126297000.x contributor: fullname: Lucidarme – volume: 4 start-page: 472 year: 1990 ident: 10.1111/apt.12362-BIB0008|apt12362-cit-0008 article-title: Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: a review of two double-blind, placebo controlled trials publication-title: Can J Gastroenterol doi: 10.1155/1990/689834 contributor: fullname: Williams – volume: 105 start-page: 501 year: 2010 ident: 10.1111/apt.12362-BIB0001|apt12362-cit-0001 article-title: UC practice guidelines in adults: American college of gastroenterology, practice parameters committee publication-title: Am J Gastroenterol doi: 10.1038/ajg.2009.727 contributor: fullname: Kornbluth – volume: 6 start-page: 991 year: 2012 ident: 10.1111/apt.12362-BIB0002|apt12362-cit-0002 article-title: Second European evidence-based consensus on the diagnosis and management of UC: current management publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2012.09.002 contributor: fullname: Dignass – volume: 5 start-page: 79 year: 1990 ident: 10.1111/apt.12362-BIB0009|apt12362-cit-0009 article-title: Topical treatment with 5-aminosalicylic in distal UC by using a new suppository preparation. A double-blind placebo controlled trial publication-title: Int J Colorectal Dis doi: 10.1007/BF00298473 contributor: fullname: Campieri – volume: 25 start-page: 663 year: 1990 ident: 10.1111/apt.12362-BIB0010|apt12362-cit-0010 article-title: Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial publication-title: Scand J Gastroenterol doi: 10.3109/00365529008997590 contributor: fullname: Campieri – volume: 12 start-page: 543 year: 2006 ident: 10.1111/apt.12362-BIB0005|apt12362-cit-0005 article-title: UC and clinical course: results of a 5-year population-based follow-up study (the IBSEN study) publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000225339.91484.fc contributor: fullname: Henriksen – volume: 32 start-page: 71S year: 1987 ident: 10.1111/apt.12362-BIB0006|apt12362-cit-0006 article-title: Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories publication-title: Dig Dis Sci doi: 10.1007/BF01312468 contributor: fullname: Williams – volume: 92 start-page: 1894 year: 1987 ident: 10.1111/apt.12362-BIB0013|apt12362-cit-0013 article-title: 5-Aminosalicylic acid enema in the treatment of distal UC, proctosigmoiditis, and proctitis publication-title: Gastroenterology doi: 10.1016/0016-5085(87)90621-4 contributor: fullname: Sutherland – volume: 8 start-page: 555 year: 1996 ident: 10.1111/apt.12362-BIB0004|apt12362-cit-0004 article-title: Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/00042737-199606000-00011 contributor: fullname: Ayres – volume: 16 start-page: 782 year: 1992 ident: 10.1111/apt.12362-BIB0011|apt12362-cit-0011 article-title: Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial publication-title: Gastroenterol Clin Biol contributor: fullname: Ngô – volume: 2 start-page: 33 year: 1988 ident: 10.1111/apt.12362-BIB0007|apt12362-cit-0007 article-title: Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.1988.tb00668.x contributor: fullname: Hogezand – volume: 31 start-page: 260 year: 1996 ident: 10.1111/apt.12362-BIB0003|apt12362-cit-0003 article-title: Changes in extent of UC: a study on the course and prognostic factors publication-title: Scand J Gastroenterol doi: 10.3109/00365529609004876 contributor: fullname: Langholz – volume: 317 start-page: 1625 year: 1987 ident: 10.1111/apt.12362-BIB0014|apt12362-cit-0014 article-title: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active UC. A randomized study publication-title: N Engl J Med doi: 10.1056/NEJM198712243172603 contributor: fullname: Schroeder – volume: 31 start-page: 260 year: 1996 ident: 10.1111/apt.12362-BIB0016|apt12362-cit-0016 article-title: Changes in extent of UC publication-title: Scand J Gastroenterol doi: 10.3109/00365529609004876 contributor: fullname: Langholz – volume: 12 start-page: 543 year: 2006 ident: 10.1111/apt.12362-BIB0018|apt12362-cit-0018 article-title: UC and clinical course: results of a 5-year population-based followed-up study (The IBSEN Study) publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000225339.91484.fc contributor: fullname: Henriksen |
SSID | ssj0006702 |
Score | 2.3773284 |
Snippet | Summary
Background
Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis.... Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. To evaluate the... BACKGROUNDMesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis.AIMTo... Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. To evaluate the... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 264 |
SubjectTerms | Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Asian Continental Ancestry Group Biological and medical sciences Colitis, Ulcerative - drug therapy Digestive system Double-Blind Method Female Gastroenterology. Liver. Pancreas. Abdomen Humans Inflammation Male Medical sciences Mesalamine - administration & dosage Mesalamine - adverse effects Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Proctitis - drug therapy Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Suppositories - administration & dosage Suppositories - adverse effects Treatment Outcome Young Adult |
Title | Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.12362 https://www.ncbi.nlm.nih.gov/pubmed/23734840 https://search.proquest.com/docview/1373435389 https://search.proquest.com/docview/1458526606 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEBYhh1Io_f9xf8K09JAevOyuvLLUnkJpCIWUEhLIoWBGYwlCN_ZSrw_tKY9Q6Bv1UfIkHcn2bre0pfQmg2SPrJnRN9LokxDPNVpSRpWpRYVphrlP7cxTyuhUo9KW3WFY7zh8pw5Osrens9Mt8Wo4C9PxQ6wW3IJlRH8dDBxt85OR42I5CtQhwf8GIr0AiI7W1FEqj_mGHGKYdKonsmcVClk8q5Ybc9G1BTb8W3x3n8XvAOcmfo0T0P4N8WEQvcs7-Thql3ZEX35hdfzPvt0U13tgCnudJt0SW666La4c9lvvd8T3I6zKmrXClTAcp4R458dLWFOGQ-2BISW4wEyB9Dk8n7sG55HFGna78jmXX0DTLmLKWB2idTiroOd4bSAsDkM7J9fRkgPFJL0GWALA6KAhOGoWgO2DX9cdv4TLi2-AELPMbH158bVPw5-zxJFF96442X9z_Pog7S-ASEkG5G-QFEo_tkpSTibLZm7qCMux1Mg4kkiXEmU5Ro_TCRnyhmQIGMmr0uao5D2xXdWVeyCAu2yy3ATN9Fk50ZbGOs-M8zOtsSSbiGeDKhSLjuejGOIjHo0ijkYidjaUZFWTQ3vDobJJxNNBawoekLD3gpWr26aYyFwyMmV4-Jc6GcduDJjGKhH3O5VbfyG052A8EbtRcf4sZLH3_jgWHv571Ufi6jRe8xESGx-L7eWn1j1hsLW0O9GqfgClNy3T |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqIgESovwVQqEMiEM5ZJVdJ46NuFSIaoFuhaqt1AuKxo4jIbbJimwOcOojIPFGPEqfhLGT7LIIEOLmSE4yiWcm3-eMPzP2VKI2Qok81CgwjDEtQp0UJiR0KlFITenQzXdMjsT4JH5zmpxusBf9WphWH2I54eYiw-drF-BuQvqnKMf5YuC0QygBX6JwTzyhOl6JR4nUVxwSyVDhSA55pyvk6niWp659ja7NsaYXU7Q7WvwOcq4jWP8JOthi73vj28qTj4NmoQfmyy-6jv_7dDfY9Q6bwn7rTDfZhi1vscuT7u_7bfb9GMu8IsewOfQrKsFv-_EcVqrhUBVAqBKsE6dA89kdn9kaZ17IGvba9hm1n0HdzH3VWOUIO3wooZN5rcHND0MzM7ZVJgfj6_RqIAsAfY4Gl6vJAAoRuly7AhMuzr8Bgi8009XF-deuEn9GFnsh3Tvs5ODV9OU47PaACA134F-hEciLSAtuUqPiOLEjazCPuESCksbInCPPIyxwNDTKFMpwxxlNIXKdouDbbLOsSnuPAT2yilPlnLOI86HUJpJprGyRSIm50QF70vtCNm-lPrKeItFoZH40Ara75iXLnsTuFbFlFbDHvdtkNCDu9wuWtmrqbMhTTuCUEOJf-sRE3wgzRSJgd1ufW93BnU98PGB73nP-bGS2_27qG_f_vesjdmU8nRxmh6-P3u6wqyO_64erc3zANhefGvuQsNdC7_oQ-wFbgDH1 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqIlVIiH9K-CkD4lAOWWXjrBPDqaKsyk-rqmqlHpCisWNLiG0Skc0BTn0EJN6IR-mTMHaSXRYBQtwcyUkm8TeTb5zxZ8aeZqi0kKIIFQoME0xtqCZWh8ROMxSZonDo5jv2D8TeSfLmdHK6xl4Ma2E6fYjFhJvzDB-vnYPXhf3JybGej5x0CMXfS4ngsYP07tFSO0qkvuCQcgwZxtmY97JCroxncerKx-hKjQ29F9ttaPE7xrlKYP0XaHqNvR9s7wpPPo7auRrpL7_IOv7nw11nV3tmCjsdlG6wNVPeZBv7_b_3W-z7EZZFRbAwBQzrKcFv-vEclprhUFkgTgnGSVOg_uyOz0yDMy9jDdtd-4zaz6Bpa18zVrl0HT6U0Iu8NuBmh6GdadPpkoP2VXoNkAWAPkKDi9RkADkIXa5bfwkX598AwZeZqeri_Gtfhz8ji72M7m12Mn11_HIv7HeACDV31F-iFshtpATXqZZJMjGx0VhEPEMiklpnBUdeRGgxHmuprdTcZYzaikKlKPgdtl5WpbnLgB5ZJql00LRJMc6UjrI0kcZOsgwLrQL2ZIBCXndCH_mQINFo5H40Ara1ApJFT8rtJeXKMmCPB9TkNCDu5wuWpmqbfMxTTtSU-OFf-iSUvBFjikTANjvILe_gzqdsPGDbHjh_NjLfOTz2jXv_3vUR2zjcnebvXh-8vc8ux37LD1fk-ICtzz-15iERr7na8g72A7oaMKQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomised+clinical+trial%3A+evaluation+of+the+efficacy+of+mesalazine+%28mesalamine%29+suppositories+in+patients+with+ulcerative+colitis+and+active+rectal+inflammation+%E2%80%93+a+placebo%E2%80%90controlled+study&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Watanabe%2C+M.&rft.au=Nishino%2C+H.&rft.au=Sameshima%2C+Y.&rft.au=Ota%2C+A.&rft.date=2013-08-01&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=38&rft.issue=3&rft.spage=264&rft.epage=273&rft_id=info:doi/10.1111%2Fapt.12362&rft.externalDBID=10.1111%252Fapt.12362&rft.externalDocID=APT12362 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |